Which of the following statement(s) is/are true concerning adjuvant systemic therapy?
A.	Adjuvant tamoxifen in post-menopausal, node-positive, ER-positive women is equivalent to cytotoxic chemotherapy
B.	Tamoxifen clearly improves survival in all hormonal receptor-positive patients
C.	CMF is associated with improved overall survival in both pre-menopausal and post-menopausal node-positive patients
D.	There is no evidence to suggest a role for chemotherapy in node-negative patients
Answer:A
Which of the following statement(s) is/are true concerning adjuvant systemic therapy?
A.	Adjuvant tamoxifen in post-menopausal, node-positive, ER-positive women is equivalent to cytotoxic chemotherapy B.	Tamoxifen clearly improves survival in all hormonal receptor-positive patients C.	CMF is associated with improved overall survival in both pre-menopausal and post-menopausal node-positive patients D.	There is no evidence to suggest a role for chemotherapy in node-negative patients